Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, tafamidis (Vyndaqel®) cannot be endorsed for use within NHS Wales for the treatment of transthyretin amyloidosis in adult patients with stage 1 symptomatic polyneuropathy to delay neurologic impairment. |
||
|
||
Medicine details |
||
| Medicine name | tafamidis (Vyndaqel®) | |
| Formulation | 20 mg capsule | |
| Reference number | 1238 | |
| Indication | For the treatment of transthyretin amyloidosis in adult patients with stage 1 symptomatic polyneuropathy to delay neurologic impairment. |
|
| Company | Pfizer Ltd | |
| BNF chapter | Central nervous system | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Ratification by Welsh Government | 25/04/2012 | |
| Date of issue | 01/05/2012 | |